Join        Login             Stock Quote

Pfizer (PFE): Lyrica Nerve-Pain Treatment Fails In Diabetes Study, Stops HIV Trial

 May 04, 2012 10:11 AM

(By Balachander) Pfizer Inc. (NYSE:PFE) said a late-stage trial of its Lyrica nerve-pain treatment failed to meet main objective of a specified change in pain and said it stopped a similar study involving patients with HIV neuropathy.

The company's phase 3 trial tested Lyrica in patients suffering with diabetes-related nerve damage.

Meanwhile, an interim analysis of a similar study in patients with neuropathic pain associated with HIV neuropathy showed that the improvements in neuropathic pain symptoms were virtually same between the Lyrica and placebo treatments.

Lyrica is not approved in the U.S. for the treatment of neuropathic pain associated with HIV neuropathy. Sales of Lyrica grew 16 percent to $955 million in the first quarter.

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

Pharmaceutical companies like Pfizer are seeking to expand use of current drugs to offset the loss of patents on key drugs.

In the United States, Lyrica capsules CV is approved to treat diabetic nerve pain, pain after shingles, fibromyalgia and partial onset seizures in adults with epilepsy who take one or more drugs for seizures.

Painful diabetic peripheral neuropathy is a form of nerve damage characterized by burning pain, pins and needles, or shooting pain in the feet and often in the hands as well. Around 20 percent of people with diabetes experience pain resulting from nerve damage, Pfizer noted.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

article imageDoes Your Latest Investment Pass This Test?

On Wednesday, I sounded the alarm about the problems looming for some consumer staples stocks. In short, read on...

article imageIs The Slump In US Manufacturing Easing?

Yesterday’s November survey data from the Philadelphia Fed hints at the possibility that a stronger trend read on...

article imageMarket Potentially Facing Near Term Technical Headwinds

After the S&P 500 Index pullback on Thursday and Friday last week, the market's advance on Monday and read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.